Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rabe

Showing results (601-610 of 646) with videos related to

Pageof 65
Sort By:
Infection|July 6, 2021
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
The Journal of Allergy and Clinical Immunology|February 6, 2021
Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammationEdgar Delgado-Eckert, Anna James, Delphine Meier-Girard, et al.
ERJ Open Research|February 18, 2025
Neutrophilic inflammation in sputum or blood does not define a clinically distinct asthma phenotype in ATLANTISPauline J M Kuks, Tessa M Kole, Monica Kraft, et al.
Infection|August 20, 2021
Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Pneumologie (Stuttgart, Germany)|September 2, 2021
[S1 Guideline Post-COVID/Long-COVID]Andreas Rembert Koczulla, Tobias Ankermann, Uta Behrends, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
Eclinicalmedicine|July 25, 2022
Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort studyThomas Bahmer, Christoph Borzikowsky, Wolfgang Lieb, et al.
Pneumologie (Stuttgart, Germany)|March 17, 2021
[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]R Buhl, R Bals, X Baur, et al.
The European Respiratory Journal|February 2, 2008
Outcomes for COPD pharmacological trials: from lung function to biomarkersM Cazzola, W MacNee, F J Martinez, et al.
Pageof 65

Showing results (601-610 of 646) with videos related to

Sort By:
Pageof 65
Infection|July 6, 2021
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
The Journal of Allergy and Clinical Immunology|February 6, 2021
Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammationEdgar Delgado-Eckert, Anna James, Delphine Meier-Girard, et al.
ERJ Open Research|February 18, 2025
Neutrophilic inflammation in sputum or blood does not define a clinically distinct asthma phenotype in ATLANTISPauline J M Kuks, Tessa M Kole, Monica Kraft, et al.
Infection|August 20, 2021
Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Pneumologie (Stuttgart, Germany)|September 2, 2021
[S1 Guideline Post-COVID/Long-COVID]Andreas Rembert Koczulla, Tobias Ankermann, Uta Behrends, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
Eclinicalmedicine|July 25, 2022
Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort studyThomas Bahmer, Christoph Borzikowsky, Wolfgang Lieb, et al.
Pneumologie (Stuttgart, Germany)|March 17, 2021
[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]R Buhl, R Bals, X Baur, et al.
The European Respiratory Journal|February 2, 2008
Outcomes for COPD pharmacological trials: from lung function to biomarkersM Cazzola, W MacNee, F J Martinez, et al.
Pageof 65